AstraZeneca’s diabetes drug Farxiga nabs coveted kidney disease nod, way ahead of rival Jardiance
AstraZeneca’s diabetes med Farxiga stormed the heart failure market with a first-in-class approval last year—and in chronic kidney disease, it just left would-be rival Jardiance in the dust. The FDA late Friday approved Farxiga, also known as dapagliflozin, to treat chronic kidney disease even in patients without diabetes. With that CKD approval in hand, Farxiga… Read More »
